Investor Insight

Zero Candida’s innovative technology poised to be a game-changer for women’s health presents a compelling investment case to gain exposure to the rapidly expanding fem-tech market.

Overview

Zero Candida (TSXV:ZCT) is a fem-tech pioneer, combining advanced artificial intelligence with non-drug diagnostics and personalized treatment modalities in a single device. Zero Candida offers an innovative, first-of-its-kind solution to the diagnosis and treatment of Candidiasis, a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva.

Founded by a team of seasoned entrepreneurs and healthcare experts, Zero Candida addresses the significant unmet needs of the women’s health market. The device offers precision therapy by eliminating fungal infections with over 99.99 percent effectiveness in just three hours, a revolutionary improvement over existing treatments.

The fem-tech market is rapidly expanding, projected to reach nearly US$30 billion by 2032. Candidiasis represents a multi-billion-dollar market, with recurrence rates creating sustained demand for effective solutions. Zero Candida’s technology provides a scalable and adaptable platform that addresses both immediate treatment needs and long-term prevention.

Zero Candida is on track to complete clinical trials and file for FDA approval in 2025. The company is listed on the TSXV and the Frankfurt Stock Exchange, expanding its market presence in North America and Europe. With its innovative technology, Zero Candida is well-positioned to set new standards in women’s health management.